AmbioPharm CALL US +1 (803) 442-7590
CAREERS   
中文
  • THE API MODEL
  • WHO WE SERVE
  • PEPTIDE PRODUCTS & SERVICES
    • GMP Services
      • Custom Peptide Synthesis
      • Custom Organic Synthesis
      • Biologically Active Peptides
    • Non-GMP Services
    • Generic Peptides
    • Vaccine Services
    • Analytical Development & Validation
  • Quality & Systems
    • Quality & Compliance
    • GMP Manufacturing
    • FDA Inspection History
  • Resources
    • Webcasts & Presentations
    • Newsroom
    • Events
    • Blog
    • FAQs
  • About Us
    • Management Team
    • Manufacturing Facilities
    • Corporate Values
  • Contact Us
  • Careers

News

News

Blog Post – Peptide Toxin-derived KV1.3 Channel Inhibitor Publication in the British Journal of Pharmacology | March 2, 2021
Blog Post – New Cyclic Peptides Review | February 9, 2021
AmbioPharm Inc. Announces New Shanghai Campus Opening and European Executive Team Members | January 7, 2021
Blog Post – Goodbye 2020: A Peptide Drug Recap and New Webcasts | January 4, 2021
Blog Post – Hope on the Horizon: Covid-19 Vaccine Update and Other Relevant Information | December 2, 2020
Upsher-Smith & AmbioPharm Announce Partnership Agreement to Develop & Market Corticotropin Injection | August 10, 2020
Adalvo and AmbioPharm partner on development & licensing for key peptide products | July 29, 2020
AmbioPharm Inc. Expands Peptide Production Helping Fight Against Covid-19 | July 1, 2020
  • AmbioPharm

    Setting a New Standard for Peptide API Manufacturing and Services

    • The API Model
    • Who We Serve
    • Peptide Products & Services
    • Quality & Systems
    • Resources
    • About Us
    • Careers
    • Corporate Values
    • Contact Us
  • CALL US +1 (803) 442-7590 CONTACT US
  • Copyright © 2021 AmbioPharm Inc.  |  Sitemap